The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

VJVirtual | Checkpoint inhibitors in the treatment of thoracic malignancies

Name: Checkpoint inhibitors in the treatment of thoracic malignancies
Uploaded: 2020-05-15T00:00:00Z
Duration: 2 min 2 s
Description: Sanjay Popat, BSc, MBBS, FRCP, PhD, of The Royal Marsden NHS Foundation Trust, London, UK, discusses a review paper published in The Journal of Thoracic Oncology around the use and role of checkpoint inhibitors in thoracic malignancies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sanjay Popat • 15 May 2020

Lung Cancer

Sanjay Popat, BSc, MBBS, FRCP, PhD, of The Royal Marsden NHS Foundation Trust, London, UK, discusses a review paper published in The Journal of Thoracic Oncology around the use and role of checkpoint inhibitors in thoracic malignancies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).